View ValuationDivi's Laboratories 将来の成長Future 基準チェック /36Divi's Laboratories利益と収益がそれぞれ年間17.3%と16.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に19.6% 17.2%なると予測されています。主要情報17.3%収益成長率17.21%EPS成長率Life Sciences 収益成長22.4%収益成長率16.8%将来の株主資本利益率19.57%アナリストカバレッジGood最終更新日08 Aug 2026今後の成長に関する最新情報Price Target Changed • Aug 03Price target increased by 10% to ₹7,829Up from ₹7,089, the current price target is an average from 30 analysts. New target price is 5.9% below last closing price of ₹8,323. Stock is up 28% over the past year. The company is forecast to post earnings per share of ₹122 for next year compared to ₹96.73 last year.Price Target Changed • Nov 11Price target increased by 7.8% to ₹4,988Up from ₹4,627, the current price target is an average from 26 analysts. New target price is 15% below last closing price of ₹5,894. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₹77.22 for next year compared to ₹60.27 last year.Price Target Changed • Aug 05Price target increased by 10% to ₹4,332Up from ₹3,922, the current price target is an average from 26 analysts. New target price is 10% below last closing price of ₹4,829. Stock is up 23% over the past year. The company is forecast to post earnings per share of ₹77.32 for next year compared to ₹60.27 last year.Price Target Changed • May 28Price target increased by 11% to ₹3,806Up from ₹3,442, the current price target is an average from 26 analysts. New target price is 13% below last closing price of ₹4,391. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹58.25 for next year compared to ₹68.69 last year.Price Target Changed • Aug 17Price target increased by 7.3% to ₹3,325Up from ₹3,098, the current price target is an average from 23 analysts. New target price is 9.2% below last closing price of ₹3,660. Stock is down 2.3% over the past year. The company is forecast to post earnings per share of ₹71.14 for next year compared to ₹68.69 last year.Price Target Changed • Feb 07Price target decreased by 14% to ₹3,064Down from ₹3,549, the current price target is an average from 24 analysts. New target price is 11% above last closing price of ₹2,749. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹71.04 for next year compared to ₹112 last year.すべての更新を表示Recent updatesPrice Target Changed • Aug 03Price target increased by 10% to ₹7,829Up from ₹7,089, the current price target is an average from 30 analysts. New target price is 5.9% below last closing price of ₹8,323. Stock is up 28% over the past year. The company is forecast to post earnings per share of ₹122 for next year compared to ₹96.73 last year.お知らせ • Jul 20Divi's Laboratories Limited to Report Q1, 2027 Results on Aug 01, 2026Divi's Laboratories Limited announced that they will report Q1, 2027 results at 9:08 AM, Indian Standard Time on Aug 01, 2026Upcoming Dividend • Jul 17Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 24 July 2026. Payment date: 09 September 2026. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.4%).Declared Dividend • May 27Dividend of ₹30.00 announcedDividend of ₹30.00 is the same as last year. Ex-date: 24th July 2026 Payment date: 9th September 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.6%. Sustainability & Growth Dividend is covered by earnings (31% earnings payout ratio) but not covered by cash flows (365% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 26Divi's Laboratories Limited announces Annual dividend, payable on September 09, 2026Divi's Laboratories Limited announced Annual dividend of INR 30.0000 per share payable on September 09, 2026, ex-date on July 24, 2026 and record date on July 24, 2026.お知らせ • May 25Divi's Laboratories Limited, Annual General Meeting, Aug 10, 2026Divi's Laboratories Limited, Annual General Meeting, Aug 10, 2026.Reported Earnings • May 24Full year 2026 earnings: Revenues and EPS in line with analyst expectationsFull year 2026 results: EPS: ₹96.75 (up from ₹82.53 in FY 2025). Revenue: ₹105.6b (up 13% from FY 2025). Net income: ₹25.7b (up 17% from FY 2025). Profit margin: 24% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year.お知らせ • May 14Divi's Laboratories Limited to Report Q4, 2026 Results on May 23, 2026Divi's Laboratories Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 23, 2026Reported Earnings • Feb 12Third quarter 2026 earnings: EPS misses analyst expectationsThird quarter 2026 results: EPS: ₹21.98 (down from ₹22.20 in 3Q 2025). Revenue: ₹26.0b (up 12% from 3Q 2025). Net income: ₹5.83b (down 1.0% from 3Q 2025). Profit margin: 22% (down from 25% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 30Divi's Laboratories Limited to Report Q3, 2026 Results on Feb 11, 2026Divi's Laboratories Limited announced that they will report Q3, 2026 results on Feb 11, 2026Reported Earnings • Nov 08Second quarter 2026 earnings released: EPS: ₹25.97 (vs ₹19.20 in 2Q 2025)Second quarter 2026 results: EPS: ₹25.97 (up from ₹19.20 in 2Q 2025). Revenue: ₹27.2b (up 16% from 2Q 2025). Net income: ₹6.89b (up 35% from 2Q 2025). Profit margin: 25% (up from 22% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 27Divi's Laboratories Limited to Report Q2, 2026 Results on Nov 07, 2025Divi's Laboratories Limited announced that they will report Q2, 2026 results on Nov 07, 2025お知らせ • Jul 26Divi's Laboratories Limited to Report Q1, 2026 Results on Aug 06, 2025Divi's Laboratories Limited announced that they will report Q1, 2026 results on Aug 06, 2025Upcoming Dividend • Jul 18Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 25 July 2025. Payment date: 10 September 2025. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). In line with average of industry peers (0.4%).Reported Earnings • Jul 15Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹82.53 (up from ₹60.27 in FY 2024). Revenue: ₹93.6b (up 19% from FY 2024). Net income: ₹21.9b (up 37% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Reported Earnings • May 23Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹82.53 (up from ₹60.27 in FY 2024). Revenue: ₹93.6b (up 19% from FY 2024). Net income: ₹21.9b (up 37% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Declared Dividend • May 21Dividend of ₹30.00 announcedDividend of ₹30.00 is the same as last year. Ex-date: 25th July 2025 Payment date: 10th September 2025 Dividend yield will be 0.5%, which is lower than the industry average of 0.6%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (168% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 20Divi's Laboratories Limited announces Annual dividend, payable on September 10, 2025Divi's Laboratories Limited announced Annual dividend of INR 30.0000 per share payable on September 10, 2025, ex-date on July 25, 2025 and record date on July 25, 2025.お知らせ • May 19Divi's Laboratories Limited, Annual General Meeting, Aug 11, 2025Divi's Laboratories Limited, Annual General Meeting, Aug 11, 2025.お知らせ • May 10Divi's Laboratories Limited to Report Q4, 2025 Results on May 17, 2025Divi's Laboratories Limited announced that they will report Q4, 2025 results at 9:08 AM, Indian Standard Time on May 17, 2025Reported Earnings • Feb 04Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹22.20 (up from ₹13.50 in 3Q 2024). Revenue: ₹23.2b (up 25% from 3Q 2024). Net income: ₹5.89b (up 65% from 3Q 2024). Profit margin: 25% (up from 19% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.お知らせ • Feb 03Divi's Laboratories Limited Appoints Manoranjan Jasti as Chief Information OfficerDivi's Laboratories Limited announced that Mr. Manoranjan Jasti serving as Chief Information Officer of the Company has been designated as Senior Management Personnel of the Company effective from February 03, 2025. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, in its meeting held on February 03, 2025, have granted approval for the terms of appointment of Mr. Manoranjan Jasti, with the specific categorization as Senior Management Personnel. Mr. Manoranjan Jasti did his Masters in Computer Networks from Middlesex University, UK in the year 2001. He holds Bachelor of Engineering in Electronics and Communication from Madras University, Chennai. He started his career as Programmer at Unisys Corporation, Uxbridge, London in 2001 and worked for multiple MNC companies in UK between 2001 to 2006. He has joined ValueLabs, Hyderabad as Senior Software Engineer in 2006 and worked there until 2017. He has joined the Company in the year 2017 as Assistant General Manager (IT) and currently serving as the Chief Information Officer of the Company overseeing the IT operations of the Company. He is responsible for overseeing all information technology (IT) aspects of a company, including developing and implementing strategic IT plans, managing data systems, ensuring data security, supporting research and development processes, and aligning technology with business goals.お知らせ • Jan 23Divi's Laboratories Limited to Report Q3, 2025 Results on Feb 03, 2025Divi's Laboratories Limited announced that they will report Q3, 2025 results on Feb 03, 2025Recent Insider Transactions • Dec 03Insider recently sold ₹30m worth of stockOn the 26th of November, Madhusudana Divi sold around 5k shares on-market at roughly ₹6,071 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹963m more than they bought in the last 12 months.Price Target Changed • Nov 11Price target increased by 7.8% to ₹4,988Up from ₹4,627, the current price target is an average from 26 analysts. New target price is 15% below last closing price of ₹5,894. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₹77.22 for next year compared to ₹60.27 last year.Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: ₹19.20 (vs ₹13.11 in 2Q 2024)Second quarter 2025 results: EPS: ₹19.20 (up from ₹13.11 in 2Q 2024). Revenue: ₹24.4b (up 28% from 2Q 2024). Net income: ₹5.10b (up 47% from 2Q 2024). Profit margin: 21% (up from 18% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Oct 29Divi's Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024Divi's Laboratories Limited announced that they will report Q2, 2025 results at 12:08 PM, Indian Standard Time on Nov 09, 2024Recent Insider Transactions • Aug 30Chief Technologist - PDSC recently sold ₹9.8m worth of stockOn the 26th of August, M. Babu sold around 2k shares on-market at roughly ₹4,905 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹59m. Insiders have been net sellers, collectively disposing of ₹843m more than they bought in the last 12 months.Recent Insider Transactions • Aug 14Insider recently sold ₹59m worth of stockOn the 7th of August, Madhusudana Divi sold around 12k shares on-market at roughly ₹4,888 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹238m. Insiders have been net sellers, collectively disposing of ₹937m more than they bought in the last 12 months.お知らせ • Aug 13Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2024Divi's Laboratories Limited announced at the AGM held on August 12, 2024, to declare dividend of INR 30/- per equity share of face value INR 2/- each (i.e. @ 1,500%) for the financial year ended March 31, 2024.Price Target Changed • Aug 05Price target increased by 10% to ₹4,332Up from ₹3,922, the current price target is an average from 26 analysts. New target price is 10% below last closing price of ₹4,829. Stock is up 23% over the past year. The company is forecast to post earnings per share of ₹77.32 for next year compared to ₹60.27 last year.Upcoming Dividend • Jul 26Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 02 August 2024. Payment date: 11 September 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.1%). In line with average of industry peers (0.6%).お知らせ • Jul 25Divi's Laboratories Limited to Report Q1, 2025 Results on Aug 03, 2024Divi's Laboratories Limited announced that they will report Q1, 2025 results at 12:08 PM, Indian Standard Time on Aug 03, 2024Reported Earnings • Jul 16Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: ₹60.27 (down from ₹68.71 in FY 2023). Revenue: ₹78.5b (up 1.0% from FY 2023). Net income: ₹16.0b (down 12% from FY 2023). Profit margin: 20% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Jun 22Divi's Laboratories Limited Announces Board and Committee ChangesDivi's Laboratories Limited announced that Mr. K.V.K Seshavataram has completed his second term as an Independent Director and consequently ceased to be a Director of the Company with effect from the close of business hours on June 22, 2024. Consequent to the cessation, Mr. K.V.K Seshavataram will also cease to be Chairman/Member of the following Board Committees of the Company from June 22, 2024: 1. Audit Committee Chaiman 2. Stakeholders Relationship Committee - Member. Further, the Board has designated Mr. K.V. Chowdary, Independent Director and member of Audit Committee of the Company, as Chairman of the Audit Committee with effect from June 23, 2024.Recent Insider Transactions • Jun 20Insider recently sold ₹46m worth of stockOn the 14th of June, Nimmagadda Anirudh sold around 10k shares on-market at roughly ₹4,597 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹238m. Insiders have been net sellers, collectively disposing of ₹896m more than they bought in the last 12 months.Recent Insider Transactions • Jun 01Insider recently sold ₹238m worth of stockOn the 29th of May, Madhusudana Divi sold around 55k shares on-market at roughly ₹4,336 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹794m more than they bought in the last 12 months.Declared Dividend • May 29Dividend of ₹30.00 announcedDividend of ₹30.00 is the same as last year. Ex-date: 2nd August 2024 Payment date: 11th September 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but not covered by cash flows (100% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 82% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Price Target Changed • May 28Price target increased by 11% to ₹3,806Up from ₹3,442, the current price target is an average from 26 analysts. New target price is 13% below last closing price of ₹4,391. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹58.25 for next year compared to ₹68.69 last year.お知らせ • May 25Divi's Laboratories Limited Recommends A Final Dividend for the Financial Year 2023-24Divi's Laboratories Limited at its board meeting, held on May 25, 2024, Recommended a final dividend of INR 30/- (i.e. 1,500%) per equity share of face value INR 2/- each for the financial year 2023-24, subject to the approval of the members at the upcoming 34th Annual General Meeting (AGM). The dividend shall be paid within specified timelines from the conclusion of the AGM. The 34th AGM of the Members of the Company will be held on August 12, 2024. The record date for the purpose of the payment of dividend is August 02, 2024.お知らせ • May 17Divi's Laboratories Limited to Report Q4, 2024 Results on May 25, 2024Divi's Laboratories Limited announced that they will report Q4, 2024 results at 12:08 PM, Indian Standard Time on May 25, 2024お知らせ • Apr 05Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing)Divi's Laboratories Limited by Postal Ballot on April 04, 2024 approved appointment of Dr. S. Devendra Rao as Whole-time Director, designated as `Whole-time Director (Manufacturing)' of the Company and approval of the remuneration payable to him.Recent Insider Transactions • Apr 02Insider recently sold ₹24m worth of stockOn the 28th of March, Madhusudana Divi sold around 7k shares on-market at roughly ₹3,394 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹112m. Insiders have been net sellers, collectively disposing of ₹543m more than they bought in the last 12 months.Recent Insider Transactions • Feb 19Chief Technologist recently sold ₹56m worth of stockOn the 14th of February, P. Rao sold around 15k shares on-market at roughly ₹3,715 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹59m. Insiders have been net sellers, collectively disposing of ₹409m more than they bought in the last 12 months.Reported Earnings • Feb 11Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: ₹13.50 (up from ₹11.56 in 3Q 2023). Revenue: ₹19.5b (up 14% from 3Q 2023). Net income: ₹3.58b (up 17% from 3Q 2023). Profit margin: 18% (in line with 3Q 2023). Revenue missed analyst estimates by 6.9%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Jan 31Divi's Laboratories Limited to Report Q3, 2024 Results on Feb 10, 2024Divi's Laboratories Limited announced that they will report Q3, 2024 results on Feb 10, 2024Recent Insider Transactions • Jan 02Insider recently sold ₹59m worth of stockOn the 28th of December, Madhusudana Divi sold around 15k shares on-market at roughly ₹3,905 per share. This transaction amounted to 5.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹348m more than they bought in the last 12 months.Recent Insider Transactions • Nov 18Non-Executive Independent Director recently sold ₹1.4m worth of stockOn the 15th of November, Gangavarapu Kumar sold around 400 shares on-market at roughly ₹3,490 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹273m more than they bought in the last 12 months.Reported Earnings • Nov 07Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: ₹13.11 (down from ₹18.34 in 2Q 2023). Revenue: ₹19.1b (up 2.9% from 2Q 2023). Net income: ₹3.48b (down 30% from 2Q 2023). Profit margin: 18% (down from 27% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 2% per year.お知らせ • Oct 28Divi's Laboratories Limited to Report Q2, 2024 Results on Nov 06, 2023Divi's Laboratories Limited announced that they will report Q2, 2024 results on Nov 06, 2023Recent Insider Transactions • Sep 22Insider recently sold ₹3.3m worth of stockOn the 15th of September, K. Sridevi sold around 870 shares on-market at roughly ₹3,820 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹294m more than they bought in the last 12 months.Recent Insider Transactions • Sep 07Chief Technologist recently sold ₹2.9m worth of stockOn the 4th of September, M. Babu sold around 800 shares on-market at roughly ₹3,629 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹282m more than they bought in the last 12 months.お知らせ • Aug 30Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2023Divi's Laboratories Limited at its 33rd Annual General Meeting held on August 28, 2023, declared dividend of INR 30/- per equity share of face value INR 2/- each (i.e., @ 1500%) for the financial year ended March 31, 2023.お知らせ • Aug 29Divi's Laboratories Limited Informs Resignations of DirectorsDivi's Laboratories Limited informed that Sri Madhusudana Rao Divi expressed his intention to retire as a Director as well as Whole-time Director of the Company in view of his age and health situation, and submitted his resignation with immediate effect to the same. A copy of his resignation letter isenclosed herewith. The Board of Directors vide its resolution dated August 28, 2023 have approved his retirement and accepted the resignation letter with immediate effect i.e. from August 28, 2023.Price Target Changed • Aug 17Price target increased by 7.3% to ₹3,325Up from ₹3,098, the current price target is an average from 23 analysts. New target price is 9.2% below last closing price of ₹3,660. Stock is down 2.3% over the past year. The company is forecast to post earnings per share of ₹71.14 for next year compared to ₹68.69 last year.New Risk • Aug 16New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 20% Last year net profit margin: 34% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Significant insider selling over the past 3 months (₹50m sold).Board Change • Aug 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Non-Executive Independent Director Kosaraju Chowdary was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Aug 05Divi's Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023Divi's Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Aug 04Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: ₹68.69 (down from ₹112 in FY 2022). Revenue: ₹77.7b (down 13% from FY 2022). Net income: ₹18.2b (down 38% from FY 2022). Profit margin: 24% (down from 33% in FY 2022). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 3.7%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.New Risk • Jul 07New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹50m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company.お知らせ • Jul 04Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023, at 10:00 Indian Standard Time.Recent Insider Transactions • May 29Insider recently sold ₹3.4m worth of stockOn the 25th of May, Y. Devi sold around 995 shares on-market at roughly ₹3,383 per share. This transaction amounted to 4.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹142m more than they bought in the last 12 months.お知らせ • May 21Divi's Laboratories Limited Recommends a Dividend for the Financial Year 2022-23Divi's Laboratories Limited at its board meeting held on May 20, 2023, recommended a Dividend of INR 30 (i.e. 1,500%) per equity share of face value INR 2 each for the financial year 2022-23, subject To Approve the members at the upcoming 33rd Annual General Meeting (AGM).Reported Earnings • May 20Full year 2023 earnings released: EPS: ₹68.69 (vs ₹112 in FY 2022)Full year 2023 results: EPS: ₹68.69 (down from ₹112 in FY 2022). Revenue: ₹81.1b (down 9.5% from FY 2022). Net income: ₹18.2b (down 38% from FY 2022). Profit margin: 23% (down from 33% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • May 13Divi's Laboratories Limited to Report Q4, 2023 Results on May 20, 2023Divi's Laboratories Limited announced that they will report Q4, 2023 results on May 20, 2023Recent Insider Transactions • Apr 01Insider recently sold ₹2.0m worth of stockOn the 28th of March, Ancha Rao sold around 700 shares on-market at roughly ₹2,798 per share. This transaction amounted to 6.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹28m. Insiders have been net sellers, collectively disposing of ₹138m more than they bought in the last 12 months.Recent Insider Transactions • Mar 17Global Quality Head recently sold ₹2.3m worth of stockOn the 13th of March, Y. T. Prasad sold around 815 shares on-market at roughly ₹2,795 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹28m. Insiders have been net sellers, collectively disposing of ₹139m more than they bought in the last 12 months.Recent Insider Transactions • Mar 10Global Quality Head recently sold ₹2.8m worth of stockOn the 6th of March, Y. T. Prasad sold around 1k shares on-market at roughly ₹2,850 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹28m. Insiders have been net sellers, collectively disposing of ₹137m more than they bought in the last 12 months.Recent Insider Transactions • Feb 12Global Quality Head recently sold ₹28m worth of stockOn the 8th of February, Y. T. Prasad sold around 10k shares on-market at roughly ₹2,800 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹155m more than they bought in the last 12 months.Price Target Changed • Feb 07Price target decreased by 14% to ₹3,064Down from ₹3,549, the current price target is an average from 24 analysts. New target price is 11% above last closing price of ₹2,749. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹71.04 for next year compared to ₹112 last year.Reported Earnings • Feb 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: EPS: ₹11.56 (down from ₹33.99 in 3Q 2022). Revenue: ₹17.1b (down 32% from 3Q 2022). Net income: ₹3.07b (down 66% from 3Q 2022). Profit margin: 18% (down from 36% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 24Divi's Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023Divi's Laboratories Limited announced that they will report Q3, 2023 results on Feb 03, 2023Recent Insider Transactions • Dec 16MD & Executive Director recently sold ₹1.0m worth of stockOn the 13th of December, Murali Krishna Divi sold around 300 shares on-market at roughly ₹3,360 per share. This transaction amounted to 7.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹91m more than they bought in the last 12 months.Recent Insider Transactions • Nov 27Insider recently sold ₹1.7m worth of stockOn the 25th of November, G. Chowdary sold around 500 shares on-market at roughly ₹3,310 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹115m more than they bought in the last 12 months.Recent Insider Transactions • Nov 20Insider recently sold ₹1.2m worth of stockOn the 17th of November, M. Krishna sold around 350 shares on-market at roughly ₹3,295 per share. This transaction amounted to 7.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹120m more than they bought in the last 12 months.Price Target Changed • Nov 16Price target decreased to ₹3,582Down from ₹4,013, the current price target is an average from 23 analysts. New target price is 8.9% above last closing price of ₹3,290. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₹83.78 for next year compared to ₹112 last year.Price Target Changed • Nov 10Price target decreased to ₹3,650Down from ₹4,013, the current price target is an average from 23 analysts. New target price is 11% above last closing price of ₹3,298. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₹83.95 for next year compared to ₹112 last year.Reported Earnings • Nov 08Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹18.60 (down from ₹22.84 in 2Q 2022). Revenue: ₹19.3b (down 2.7% from 2Q 2022). Net income: ₹4.94b (down 19% from 2Q 2022). Profit margin: 26% (down from 31% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 26% per year.Recent Insider Transactions • Sep 30Insider recently sold ₹1.5m worth of stockOn the 27th of September, Radhika Dronavalli sold around 400 shares on-market at roughly ₹3,663 per share. This transaction amounted to 42% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.8m. Insiders have been net sellers, collectively disposing of ₹94m more than they bought in the last 12 months.Recent Insider Transactions • Sep 16Insider recently sold ₹3.7m worth of stockOn the 13th of September, Lavu Srinidhi sold around 1k shares on-market at roughly ₹3,701 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹89m more than they bought in the last 12 months.Upcoming Dividend • Aug 04Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 11 August 2022. Payment date: 21 September 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.7%). In line with average of industry peers (0.7%).お知らせ • Jul 30Divi's Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Divi's Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022Reported Earnings • Jul 26Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₹112 (up from ₹74.75 in FY 2021). Revenue: ₹89.6b (up 29% from FY 2021). Net income: ₹29.6b (up 49% from FY 2021). Profit margin: 33% (up from 28% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.0%. Over the next year, revenue is forecast to grow 1.8%, compared to a 37% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 31% per year.お知らせ • Jul 06Divi's Laboratories Limited Recommends DividendDivi's Laboratories Limited recommended a dividend of INR 30 per equity share of INR 2 each (i.e. 1500%) for the financial year 2021-22, subject To Approve the shareholders at the AGM scheduled to be held on August 22, 2022.お知らせ • Jul 05Divi's Laboratories Limited, Annual General Meeting, Aug 22, 2022Divi's Laboratories Limited, Annual General Meeting, Aug 22, 2022, at 10:00 Indian Standard Time.Recent Insider Transactions • Jul 02Insider recently sold ₹2.5m worth of stockOn the 30th of June, Y. Rao sold around 700 shares on-market at roughly ₹3,585 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹102m more than they bought in the last 12 months.Recent Insider Transactions • Jun 11Insider recently sold ₹7.3m worth of stockOn the 8th of June, S. Rao sold around 2k shares on-market at roughly ₹3,510 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.1m. Insiders have been net sellers, collectively disposing of ₹234m more than they bought in the last 12 months.お知らせ • May 24Divi's Laboratories Limited Recommends A Dividend for the Year 2021-2022The board of directors of Divi's Laboratories Limited meeting held on May 23, 2022, recommended a Dividend of INR 30 (i.e. 1500%) per equity share of face value INR 2/- each for the financial year 2021-22, subject To Approve the members at the upcoming 32 nd Annual General Meeting (AGM). The dividend shall be credited/warrants thereof dispatched within 30 (thirty) days from the conclusion of the AGM. The AGM date and book closure /record date for the purpose of the payment of dividend will be informed in due course.Price Target Changed • May 24Price target decreased to ₹4,466Down from ₹4,804, the current price target is an average from 16 analysts. New target price is 22% above last closing price of ₹3,662. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₹97.81 for next year compared to ₹112 last year.お知らせ • May 14Divi's Laboratories Limited to Report Q4, 2022 Results on May 23, 2022Divi's Laboratories Limited announced that they will report Q4, 2022 results on May 23, 2022Recent Insider Transactions • Mar 28Insider recently sold ₹2.7m worth of stockOn the 23rd of March, Sandya Chittineni sold around 600 shares on-market at roughly ₹4,545 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹21m. Insiders have been net sellers, collectively disposing of ₹252m more than they bought in the last 12 months.Recent Insider Transactions • Mar 17Board Member recently sold ₹21m worth of stockOn the 10th of March, Madhusudana Divi sold around 5k shares on-market at roughly ₹4,289 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹247m more than they bought in the last 12 months.Recent Insider Transactions • Feb 27Insider recently bought ₹796k worth of stockOn the 24th of February, Manjula Pasumarthy bought around 200 shares on-market at roughly ₹3,980 per share. In the last 3 months, they made an even bigger purchase worth ₹2.5m. Despite this recent purchase, insiders have collectively sold ₹226m more in shares than they bought in the last 12 months.Reported Earnings • Feb 13Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: ₹33.99 (up from ₹17.73 in 3Q 2021). Revenue: ₹24.9b (up 47% from 3Q 2021). Net income: ₹9.02b (up 92% from 3Q 2021). Profit margin: 36% (up from 28% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 14%, compared to a 33% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Dec 20Insider recently bought ₹1.1m worth of stockOn the 16th of December, Y. Rao bought around 229 shares on-market at roughly ₹4,609 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.9m. Despite this recent purchase, insiders have collectively sold ₹211m more in shares than they bought in the last 12 months.Reported Earnings • Nov 07Second quarter 2022 earnings released: EPS ₹22.84 (vs ₹19.57 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹20.1b (up 15% from 2Q 2021). Net income: ₹6.06b (up 17% from 2Q 2021). Profit margin: 30% (in line with 2Q 2021).Recent Insider Transactions • Sep 30Insider recently sold ₹1.3m worth of stockOn the 23rd of September, K. Sreehari sold around 250 shares on-market at roughly ₹5,159 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹348m more than they bought in the last 12 months.業績と収益の成長予測BSE:532488 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2029178,49847,25723,855N/A163/31/2028149,88839,36617,983N/A293/31/2027125,66332,56912,653N/A296/30/2026112,30029,250N/AN/AN/A3/31/2026105,60025,6802,18027,380N/A12/31/2025103,14024,790N/AN/AN/A9/30/2025100,29024,85054023,720N/A6/30/202596,52023,060N/AN/AN/A3/31/202593,60021,9102,15016,530N/A12/31/202490,78020,670N/AN/AN/A9/30/202486,14018,3604,75016,480N/A6/30/202481,85016,740N/AN/AN/A3/31/202478,45016,0002,58012,610N/A12/31/202374,92613,834N/AN/AN/A9/30/202373,45613,3147,92715,127N/A6/30/202372,90614,774N/AN/AN/A3/31/202377,67018,24019,86024,590N/A12/31/202283,35323,971N/AN/AN/A9/30/202291,20829,92522,15328,404N/A6/30/202292,53831,054N/AN/AN/A3/31/202289,59929,60511,98619,118N/A12/31/202182,29725,678N/AN/AN/A9/30/202174,37921,3624,76013,465N/A6/30/202171,99620,493N/AN/AN/A3/31/202169,69519,84310,36719,469N/A12/31/202065,71018,705N/AN/AN/A9/30/202062,65817,59010,71420,167N/A6/30/202059,62015,962N/AN/AN/A3/31/202053,94513,765N/A12,159N/A12/31/201952,71912,803N/AN/AN/A9/30/201952,35613,106N/A7,962N/A6/30/201951,13913,575N/AN/AN/A3/31/201949,46313,527N/A9,543N/A3/31/201838,9158,770N/A7,759N/A3/31/201740,64310,604N/A11,504N/A3/31/201637,76411,258N/A10,379N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 532488の予測収益成長率 (年間17.3% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: 532488の収益 ( 17.3% ) はIndian市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: 532488の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 532488の収益 ( 16.8% ) Indian市場 ( 11.1% ) よりも速いペースで成長すると予測されています。高い収益成長: 532488の収益 ( 16.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 532488の 自己資本利益率 は、3年後には低くなると予測されています ( 19.6 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/15 04:03終値2026/08/14 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Divi's Laboratories Limited 29 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedPranav ChawlaAmbit CapitalGaurav TinaniAmbit Capital50 その他のアナリストを表示
Price Target Changed • Aug 03Price target increased by 10% to ₹7,829Up from ₹7,089, the current price target is an average from 30 analysts. New target price is 5.9% below last closing price of ₹8,323. Stock is up 28% over the past year. The company is forecast to post earnings per share of ₹122 for next year compared to ₹96.73 last year.
Price Target Changed • Nov 11Price target increased by 7.8% to ₹4,988Up from ₹4,627, the current price target is an average from 26 analysts. New target price is 15% below last closing price of ₹5,894. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₹77.22 for next year compared to ₹60.27 last year.
Price Target Changed • Aug 05Price target increased by 10% to ₹4,332Up from ₹3,922, the current price target is an average from 26 analysts. New target price is 10% below last closing price of ₹4,829. Stock is up 23% over the past year. The company is forecast to post earnings per share of ₹77.32 for next year compared to ₹60.27 last year.
Price Target Changed • May 28Price target increased by 11% to ₹3,806Up from ₹3,442, the current price target is an average from 26 analysts. New target price is 13% below last closing price of ₹4,391. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹58.25 for next year compared to ₹68.69 last year.
Price Target Changed • Aug 17Price target increased by 7.3% to ₹3,325Up from ₹3,098, the current price target is an average from 23 analysts. New target price is 9.2% below last closing price of ₹3,660. Stock is down 2.3% over the past year. The company is forecast to post earnings per share of ₹71.14 for next year compared to ₹68.69 last year.
Price Target Changed • Feb 07Price target decreased by 14% to ₹3,064Down from ₹3,549, the current price target is an average from 24 analysts. New target price is 11% above last closing price of ₹2,749. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹71.04 for next year compared to ₹112 last year.
Price Target Changed • Aug 03Price target increased by 10% to ₹7,829Up from ₹7,089, the current price target is an average from 30 analysts. New target price is 5.9% below last closing price of ₹8,323. Stock is up 28% over the past year. The company is forecast to post earnings per share of ₹122 for next year compared to ₹96.73 last year.
お知らせ • Jul 20Divi's Laboratories Limited to Report Q1, 2027 Results on Aug 01, 2026Divi's Laboratories Limited announced that they will report Q1, 2027 results at 9:08 AM, Indian Standard Time on Aug 01, 2026
Upcoming Dividend • Jul 17Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 24 July 2026. Payment date: 09 September 2026. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.4%).
Declared Dividend • May 27Dividend of ₹30.00 announcedDividend of ₹30.00 is the same as last year. Ex-date: 24th July 2026 Payment date: 9th September 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.6%. Sustainability & Growth Dividend is covered by earnings (31% earnings payout ratio) but not covered by cash flows (365% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 26Divi's Laboratories Limited announces Annual dividend, payable on September 09, 2026Divi's Laboratories Limited announced Annual dividend of INR 30.0000 per share payable on September 09, 2026, ex-date on July 24, 2026 and record date on July 24, 2026.
お知らせ • May 25Divi's Laboratories Limited, Annual General Meeting, Aug 10, 2026Divi's Laboratories Limited, Annual General Meeting, Aug 10, 2026.
Reported Earnings • May 24Full year 2026 earnings: Revenues and EPS in line with analyst expectationsFull year 2026 results: EPS: ₹96.75 (up from ₹82.53 in FY 2025). Revenue: ₹105.6b (up 13% from FY 2025). Net income: ₹25.7b (up 17% from FY 2025). Profit margin: 24% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year.
お知らせ • May 14Divi's Laboratories Limited to Report Q4, 2026 Results on May 23, 2026Divi's Laboratories Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 23, 2026
Reported Earnings • Feb 12Third quarter 2026 earnings: EPS misses analyst expectationsThird quarter 2026 results: EPS: ₹21.98 (down from ₹22.20 in 3Q 2025). Revenue: ₹26.0b (up 12% from 3Q 2025). Net income: ₹5.83b (down 1.0% from 3Q 2025). Profit margin: 22% (down from 25% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 30Divi's Laboratories Limited to Report Q3, 2026 Results on Feb 11, 2026Divi's Laboratories Limited announced that they will report Q3, 2026 results on Feb 11, 2026
Reported Earnings • Nov 08Second quarter 2026 earnings released: EPS: ₹25.97 (vs ₹19.20 in 2Q 2025)Second quarter 2026 results: EPS: ₹25.97 (up from ₹19.20 in 2Q 2025). Revenue: ₹27.2b (up 16% from 2Q 2025). Net income: ₹6.89b (up 35% from 2Q 2025). Profit margin: 25% (up from 22% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 27Divi's Laboratories Limited to Report Q2, 2026 Results on Nov 07, 2025Divi's Laboratories Limited announced that they will report Q2, 2026 results on Nov 07, 2025
お知らせ • Jul 26Divi's Laboratories Limited to Report Q1, 2026 Results on Aug 06, 2025Divi's Laboratories Limited announced that they will report Q1, 2026 results on Aug 06, 2025
Upcoming Dividend • Jul 18Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 25 July 2025. Payment date: 10 September 2025. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). In line with average of industry peers (0.4%).
Reported Earnings • Jul 15Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹82.53 (up from ₹60.27 in FY 2024). Revenue: ₹93.6b (up 19% from FY 2024). Net income: ₹21.9b (up 37% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Reported Earnings • May 23Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹82.53 (up from ₹60.27 in FY 2024). Revenue: ₹93.6b (up 19% from FY 2024). Net income: ₹21.9b (up 37% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Declared Dividend • May 21Dividend of ₹30.00 announcedDividend of ₹30.00 is the same as last year. Ex-date: 25th July 2025 Payment date: 10th September 2025 Dividend yield will be 0.5%, which is lower than the industry average of 0.6%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (168% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 20Divi's Laboratories Limited announces Annual dividend, payable on September 10, 2025Divi's Laboratories Limited announced Annual dividend of INR 30.0000 per share payable on September 10, 2025, ex-date on July 25, 2025 and record date on July 25, 2025.
お知らせ • May 19Divi's Laboratories Limited, Annual General Meeting, Aug 11, 2025Divi's Laboratories Limited, Annual General Meeting, Aug 11, 2025.
お知らせ • May 10Divi's Laboratories Limited to Report Q4, 2025 Results on May 17, 2025Divi's Laboratories Limited announced that they will report Q4, 2025 results at 9:08 AM, Indian Standard Time on May 17, 2025
Reported Earnings • Feb 04Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: ₹22.20 (up from ₹13.50 in 3Q 2024). Revenue: ₹23.2b (up 25% from 3Q 2024). Net income: ₹5.89b (up 65% from 3Q 2024). Profit margin: 25% (up from 19% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
お知らせ • Feb 03Divi's Laboratories Limited Appoints Manoranjan Jasti as Chief Information OfficerDivi's Laboratories Limited announced that Mr. Manoranjan Jasti serving as Chief Information Officer of the Company has been designated as Senior Management Personnel of the Company effective from February 03, 2025. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, in its meeting held on February 03, 2025, have granted approval for the terms of appointment of Mr. Manoranjan Jasti, with the specific categorization as Senior Management Personnel. Mr. Manoranjan Jasti did his Masters in Computer Networks from Middlesex University, UK in the year 2001. He holds Bachelor of Engineering in Electronics and Communication from Madras University, Chennai. He started his career as Programmer at Unisys Corporation, Uxbridge, London in 2001 and worked for multiple MNC companies in UK between 2001 to 2006. He has joined ValueLabs, Hyderabad as Senior Software Engineer in 2006 and worked there until 2017. He has joined the Company in the year 2017 as Assistant General Manager (IT) and currently serving as the Chief Information Officer of the Company overseeing the IT operations of the Company. He is responsible for overseeing all information technology (IT) aspects of a company, including developing and implementing strategic IT plans, managing data systems, ensuring data security, supporting research and development processes, and aligning technology with business goals.
お知らせ • Jan 23Divi's Laboratories Limited to Report Q3, 2025 Results on Feb 03, 2025Divi's Laboratories Limited announced that they will report Q3, 2025 results on Feb 03, 2025
Recent Insider Transactions • Dec 03Insider recently sold ₹30m worth of stockOn the 26th of November, Madhusudana Divi sold around 5k shares on-market at roughly ₹6,071 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹963m more than they bought in the last 12 months.
Price Target Changed • Nov 11Price target increased by 7.8% to ₹4,988Up from ₹4,627, the current price target is an average from 26 analysts. New target price is 15% below last closing price of ₹5,894. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₹77.22 for next year compared to ₹60.27 last year.
Reported Earnings • Nov 10Second quarter 2025 earnings released: EPS: ₹19.20 (vs ₹13.11 in 2Q 2024)Second quarter 2025 results: EPS: ₹19.20 (up from ₹13.11 in 2Q 2024). Revenue: ₹24.4b (up 28% from 2Q 2024). Net income: ₹5.10b (up 47% from 2Q 2024). Profit margin: 21% (up from 18% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Oct 29Divi's Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024Divi's Laboratories Limited announced that they will report Q2, 2025 results at 12:08 PM, Indian Standard Time on Nov 09, 2024
Recent Insider Transactions • Aug 30Chief Technologist - PDSC recently sold ₹9.8m worth of stockOn the 26th of August, M. Babu sold around 2k shares on-market at roughly ₹4,905 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹59m. Insiders have been net sellers, collectively disposing of ₹843m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 14Insider recently sold ₹59m worth of stockOn the 7th of August, Madhusudana Divi sold around 12k shares on-market at roughly ₹4,888 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹238m. Insiders have been net sellers, collectively disposing of ₹937m more than they bought in the last 12 months.
お知らせ • Aug 13Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2024Divi's Laboratories Limited announced at the AGM held on August 12, 2024, to declare dividend of INR 30/- per equity share of face value INR 2/- each (i.e. @ 1,500%) for the financial year ended March 31, 2024.
Price Target Changed • Aug 05Price target increased by 10% to ₹4,332Up from ₹3,922, the current price target is an average from 26 analysts. New target price is 10% below last closing price of ₹4,829. Stock is up 23% over the past year. The company is forecast to post earnings per share of ₹77.32 for next year compared to ₹60.27 last year.
Upcoming Dividend • Jul 26Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 02 August 2024. Payment date: 11 September 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.1%). In line with average of industry peers (0.6%).
お知らせ • Jul 25Divi's Laboratories Limited to Report Q1, 2025 Results on Aug 03, 2024Divi's Laboratories Limited announced that they will report Q1, 2025 results at 12:08 PM, Indian Standard Time on Aug 03, 2024
Reported Earnings • Jul 16Full year 2024 earnings: EPS and revenues exceed analyst expectationsFull year 2024 results: EPS: ₹60.27 (down from ₹68.71 in FY 2023). Revenue: ₹78.5b (up 1.0% from FY 2023). Net income: ₹16.0b (down 12% from FY 2023). Profit margin: 20% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 22Divi's Laboratories Limited Announces Board and Committee ChangesDivi's Laboratories Limited announced that Mr. K.V.K Seshavataram has completed his second term as an Independent Director and consequently ceased to be a Director of the Company with effect from the close of business hours on June 22, 2024. Consequent to the cessation, Mr. K.V.K Seshavataram will also cease to be Chairman/Member of the following Board Committees of the Company from June 22, 2024: 1. Audit Committee Chaiman 2. Stakeholders Relationship Committee - Member. Further, the Board has designated Mr. K.V. Chowdary, Independent Director and member of Audit Committee of the Company, as Chairman of the Audit Committee with effect from June 23, 2024.
Recent Insider Transactions • Jun 20Insider recently sold ₹46m worth of stockOn the 14th of June, Nimmagadda Anirudh sold around 10k shares on-market at roughly ₹4,597 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹238m. Insiders have been net sellers, collectively disposing of ₹896m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 01Insider recently sold ₹238m worth of stockOn the 29th of May, Madhusudana Divi sold around 55k shares on-market at roughly ₹4,336 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹794m more than they bought in the last 12 months.
Declared Dividend • May 29Dividend of ₹30.00 announcedDividend of ₹30.00 is the same as last year. Ex-date: 2nd August 2024 Payment date: 11th September 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but not covered by cash flows (100% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 82% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Price Target Changed • May 28Price target increased by 11% to ₹3,806Up from ₹3,442, the current price target is an average from 26 analysts. New target price is 13% below last closing price of ₹4,391. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹58.25 for next year compared to ₹68.69 last year.
お知らせ • May 25Divi's Laboratories Limited Recommends A Final Dividend for the Financial Year 2023-24Divi's Laboratories Limited at its board meeting, held on May 25, 2024, Recommended a final dividend of INR 30/- (i.e. 1,500%) per equity share of face value INR 2/- each for the financial year 2023-24, subject to the approval of the members at the upcoming 34th Annual General Meeting (AGM). The dividend shall be paid within specified timelines from the conclusion of the AGM. The 34th AGM of the Members of the Company will be held on August 12, 2024. The record date for the purpose of the payment of dividend is August 02, 2024.
お知らせ • May 17Divi's Laboratories Limited to Report Q4, 2024 Results on May 25, 2024Divi's Laboratories Limited announced that they will report Q4, 2024 results at 12:08 PM, Indian Standard Time on May 25, 2024
お知らせ • Apr 05Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing)Divi's Laboratories Limited by Postal Ballot on April 04, 2024 approved appointment of Dr. S. Devendra Rao as Whole-time Director, designated as `Whole-time Director (Manufacturing)' of the Company and approval of the remuneration payable to him.
Recent Insider Transactions • Apr 02Insider recently sold ₹24m worth of stockOn the 28th of March, Madhusudana Divi sold around 7k shares on-market at roughly ₹3,394 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹112m. Insiders have been net sellers, collectively disposing of ₹543m more than they bought in the last 12 months.
Recent Insider Transactions • Feb 19Chief Technologist recently sold ₹56m worth of stockOn the 14th of February, P. Rao sold around 15k shares on-market at roughly ₹3,715 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹59m. Insiders have been net sellers, collectively disposing of ₹409m more than they bought in the last 12 months.
Reported Earnings • Feb 11Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: ₹13.50 (up from ₹11.56 in 3Q 2023). Revenue: ₹19.5b (up 14% from 3Q 2023). Net income: ₹3.58b (up 17% from 3Q 2023). Profit margin: 18% (in line with 3Q 2023). Revenue missed analyst estimates by 6.9%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 31Divi's Laboratories Limited to Report Q3, 2024 Results on Feb 10, 2024Divi's Laboratories Limited announced that they will report Q3, 2024 results on Feb 10, 2024
Recent Insider Transactions • Jan 02Insider recently sold ₹59m worth of stockOn the 28th of December, Madhusudana Divi sold around 15k shares on-market at roughly ₹3,905 per share. This transaction amounted to 5.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹348m more than they bought in the last 12 months.
Recent Insider Transactions • Nov 18Non-Executive Independent Director recently sold ₹1.4m worth of stockOn the 15th of November, Gangavarapu Kumar sold around 400 shares on-market at roughly ₹3,490 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹273m more than they bought in the last 12 months.
Reported Earnings • Nov 07Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: ₹13.11 (down from ₹18.34 in 2Q 2023). Revenue: ₹19.1b (up 2.9% from 2Q 2023). Net income: ₹3.48b (down 30% from 2Q 2023). Profit margin: 18% (down from 27% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 2% per year.
お知らせ • Oct 28Divi's Laboratories Limited to Report Q2, 2024 Results on Nov 06, 2023Divi's Laboratories Limited announced that they will report Q2, 2024 results on Nov 06, 2023
Recent Insider Transactions • Sep 22Insider recently sold ₹3.3m worth of stockOn the 15th of September, K. Sridevi sold around 870 shares on-market at roughly ₹3,820 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹294m more than they bought in the last 12 months.
Recent Insider Transactions • Sep 07Chief Technologist recently sold ₹2.9m worth of stockOn the 4th of September, M. Babu sold around 800 shares on-market at roughly ₹3,629 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹282m more than they bought in the last 12 months.
お知らせ • Aug 30Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2023Divi's Laboratories Limited at its 33rd Annual General Meeting held on August 28, 2023, declared dividend of INR 30/- per equity share of face value INR 2/- each (i.e., @ 1500%) for the financial year ended March 31, 2023.
お知らせ • Aug 29Divi's Laboratories Limited Informs Resignations of DirectorsDivi's Laboratories Limited informed that Sri Madhusudana Rao Divi expressed his intention to retire as a Director as well as Whole-time Director of the Company in view of his age and health situation, and submitted his resignation with immediate effect to the same. A copy of his resignation letter isenclosed herewith. The Board of Directors vide its resolution dated August 28, 2023 have approved his retirement and accepted the resignation letter with immediate effect i.e. from August 28, 2023.
Price Target Changed • Aug 17Price target increased by 7.3% to ₹3,325Up from ₹3,098, the current price target is an average from 23 analysts. New target price is 9.2% below last closing price of ₹3,660. Stock is down 2.3% over the past year. The company is forecast to post earnings per share of ₹71.14 for next year compared to ₹68.69 last year.
New Risk • Aug 16New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 20% Last year net profit margin: 34% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Significant insider selling over the past 3 months (₹50m sold).
Board Change • Aug 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Non-Executive Independent Director Kosaraju Chowdary was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Aug 05Divi's Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023Divi's Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Aug 04Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: ₹68.69 (down from ₹112 in FY 2022). Revenue: ₹77.7b (down 13% from FY 2022). Net income: ₹18.2b (down 38% from FY 2022). Profit margin: 24% (down from 33% in FY 2022). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 3.7%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
New Risk • Jul 07New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹50m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company.
お知らせ • Jul 04Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023, at 10:00 Indian Standard Time.
Recent Insider Transactions • May 29Insider recently sold ₹3.4m worth of stockOn the 25th of May, Y. Devi sold around 995 shares on-market at roughly ₹3,383 per share. This transaction amounted to 4.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹142m more than they bought in the last 12 months.
お知らせ • May 21Divi's Laboratories Limited Recommends a Dividend for the Financial Year 2022-23Divi's Laboratories Limited at its board meeting held on May 20, 2023, recommended a Dividend of INR 30 (i.e. 1,500%) per equity share of face value INR 2 each for the financial year 2022-23, subject To Approve the members at the upcoming 33rd Annual General Meeting (AGM).
Reported Earnings • May 20Full year 2023 earnings released: EPS: ₹68.69 (vs ₹112 in FY 2022)Full year 2023 results: EPS: ₹68.69 (down from ₹112 in FY 2022). Revenue: ₹81.1b (down 9.5% from FY 2022). Net income: ₹18.2b (down 38% from FY 2022). Profit margin: 23% (down from 33% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • May 13Divi's Laboratories Limited to Report Q4, 2023 Results on May 20, 2023Divi's Laboratories Limited announced that they will report Q4, 2023 results on May 20, 2023
Recent Insider Transactions • Apr 01Insider recently sold ₹2.0m worth of stockOn the 28th of March, Ancha Rao sold around 700 shares on-market at roughly ₹2,798 per share. This transaction amounted to 6.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹28m. Insiders have been net sellers, collectively disposing of ₹138m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 17Global Quality Head recently sold ₹2.3m worth of stockOn the 13th of March, Y. T. Prasad sold around 815 shares on-market at roughly ₹2,795 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹28m. Insiders have been net sellers, collectively disposing of ₹139m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 10Global Quality Head recently sold ₹2.8m worth of stockOn the 6th of March, Y. T. Prasad sold around 1k shares on-market at roughly ₹2,850 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹28m. Insiders have been net sellers, collectively disposing of ₹137m more than they bought in the last 12 months.
Recent Insider Transactions • Feb 12Global Quality Head recently sold ₹28m worth of stockOn the 8th of February, Y. T. Prasad sold around 10k shares on-market at roughly ₹2,800 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹155m more than they bought in the last 12 months.
Price Target Changed • Feb 07Price target decreased by 14% to ₹3,064Down from ₹3,549, the current price target is an average from 24 analysts. New target price is 11% above last closing price of ₹2,749. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹71.04 for next year compared to ₹112 last year.
Reported Earnings • Feb 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: EPS: ₹11.56 (down from ₹33.99 in 3Q 2022). Revenue: ₹17.1b (down 32% from 3Q 2022). Net income: ₹3.07b (down 66% from 3Q 2022). Profit margin: 18% (down from 36% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 24Divi's Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023Divi's Laboratories Limited announced that they will report Q3, 2023 results on Feb 03, 2023
Recent Insider Transactions • Dec 16MD & Executive Director recently sold ₹1.0m worth of stockOn the 13th of December, Murali Krishna Divi sold around 300 shares on-market at roughly ₹3,360 per share. This transaction amounted to 7.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹91m more than they bought in the last 12 months.
Recent Insider Transactions • Nov 27Insider recently sold ₹1.7m worth of stockOn the 25th of November, G. Chowdary sold around 500 shares on-market at roughly ₹3,310 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹115m more than they bought in the last 12 months.
Recent Insider Transactions • Nov 20Insider recently sold ₹1.2m worth of stockOn the 17th of November, M. Krishna sold around 350 shares on-market at roughly ₹3,295 per share. This transaction amounted to 7.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹120m more than they bought in the last 12 months.
Price Target Changed • Nov 16Price target decreased to ₹3,582Down from ₹4,013, the current price target is an average from 23 analysts. New target price is 8.9% above last closing price of ₹3,290. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₹83.78 for next year compared to ₹112 last year.
Price Target Changed • Nov 10Price target decreased to ₹3,650Down from ₹4,013, the current price target is an average from 23 analysts. New target price is 11% above last closing price of ₹3,298. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₹83.95 for next year compared to ₹112 last year.
Reported Earnings • Nov 08Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹18.60 (down from ₹22.84 in 2Q 2022). Revenue: ₹19.3b (down 2.7% from 2Q 2022). Net income: ₹4.94b (down 19% from 2Q 2022). Profit margin: 26% (down from 31% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 26% per year.
Recent Insider Transactions • Sep 30Insider recently sold ₹1.5m worth of stockOn the 27th of September, Radhika Dronavalli sold around 400 shares on-market at roughly ₹3,663 per share. This transaction amounted to 42% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.8m. Insiders have been net sellers, collectively disposing of ₹94m more than they bought in the last 12 months.
Recent Insider Transactions • Sep 16Insider recently sold ₹3.7m worth of stockOn the 13th of September, Lavu Srinidhi sold around 1k shares on-market at roughly ₹3,701 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹89m more than they bought in the last 12 months.
Upcoming Dividend • Aug 04Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 11 August 2022. Payment date: 21 September 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.7%). In line with average of industry peers (0.7%).
お知らせ • Jul 30Divi's Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Divi's Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022
Reported Earnings • Jul 26Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₹112 (up from ₹74.75 in FY 2021). Revenue: ₹89.6b (up 29% from FY 2021). Net income: ₹29.6b (up 49% from FY 2021). Profit margin: 33% (up from 28% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.0%. Over the next year, revenue is forecast to grow 1.8%, compared to a 37% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 31% per year.
お知らせ • Jul 06Divi's Laboratories Limited Recommends DividendDivi's Laboratories Limited recommended a dividend of INR 30 per equity share of INR 2 each (i.e. 1500%) for the financial year 2021-22, subject To Approve the shareholders at the AGM scheduled to be held on August 22, 2022.
お知らせ • Jul 05Divi's Laboratories Limited, Annual General Meeting, Aug 22, 2022Divi's Laboratories Limited, Annual General Meeting, Aug 22, 2022, at 10:00 Indian Standard Time.
Recent Insider Transactions • Jul 02Insider recently sold ₹2.5m worth of stockOn the 30th of June, Y. Rao sold around 700 shares on-market at roughly ₹3,585 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹102m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 11Insider recently sold ₹7.3m worth of stockOn the 8th of June, S. Rao sold around 2k shares on-market at roughly ₹3,510 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.1m. Insiders have been net sellers, collectively disposing of ₹234m more than they bought in the last 12 months.
お知らせ • May 24Divi's Laboratories Limited Recommends A Dividend for the Year 2021-2022The board of directors of Divi's Laboratories Limited meeting held on May 23, 2022, recommended a Dividend of INR 30 (i.e. 1500%) per equity share of face value INR 2/- each for the financial year 2021-22, subject To Approve the members at the upcoming 32 nd Annual General Meeting (AGM). The dividend shall be credited/warrants thereof dispatched within 30 (thirty) days from the conclusion of the AGM. The AGM date and book closure /record date for the purpose of the payment of dividend will be informed in due course.
Price Target Changed • May 24Price target decreased to ₹4,466Down from ₹4,804, the current price target is an average from 16 analysts. New target price is 22% above last closing price of ₹3,662. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₹97.81 for next year compared to ₹112 last year.
お知らせ • May 14Divi's Laboratories Limited to Report Q4, 2022 Results on May 23, 2022Divi's Laboratories Limited announced that they will report Q4, 2022 results on May 23, 2022
Recent Insider Transactions • Mar 28Insider recently sold ₹2.7m worth of stockOn the 23rd of March, Sandya Chittineni sold around 600 shares on-market at roughly ₹4,545 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹21m. Insiders have been net sellers, collectively disposing of ₹252m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 17Board Member recently sold ₹21m worth of stockOn the 10th of March, Madhusudana Divi sold around 5k shares on-market at roughly ₹4,289 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹247m more than they bought in the last 12 months.
Recent Insider Transactions • Feb 27Insider recently bought ₹796k worth of stockOn the 24th of February, Manjula Pasumarthy bought around 200 shares on-market at roughly ₹3,980 per share. In the last 3 months, they made an even bigger purchase worth ₹2.5m. Despite this recent purchase, insiders have collectively sold ₹226m more in shares than they bought in the last 12 months.
Reported Earnings • Feb 13Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: ₹33.99 (up from ₹17.73 in 3Q 2021). Revenue: ₹24.9b (up 47% from 3Q 2021). Net income: ₹9.02b (up 92% from 3Q 2021). Profit margin: 36% (up from 28% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 14%, compared to a 33% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Dec 20Insider recently bought ₹1.1m worth of stockOn the 16th of December, Y. Rao bought around 229 shares on-market at roughly ₹4,609 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.9m. Despite this recent purchase, insiders have collectively sold ₹211m more in shares than they bought in the last 12 months.
Reported Earnings • Nov 07Second quarter 2022 earnings released: EPS ₹22.84 (vs ₹19.57 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹20.1b (up 15% from 2Q 2021). Net income: ₹6.06b (up 17% from 2Q 2021). Profit margin: 30% (in line with 2Q 2021).
Recent Insider Transactions • Sep 30Insider recently sold ₹1.3m worth of stockOn the 23rd of September, K. Sreehari sold around 250 shares on-market at roughly ₹5,159 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹348m more than they bought in the last 12 months.